Medicinski Centar Po Otcni Bolesti D-R Marinovi OOD
- Address
- Ulitsa Tsar Osvoboditel 108, 9700 Shumen, Bulgaria
Medicinski Centar Po Otcni Bolesti D-R Marinovi OOD - Ophthalmology Research Center
Medicinski Centar Po Otcni Bolesti D-R Marinovi OOD is a specialized ophthalmology research center with expertise in retinal disease studies. The center demonstrates particular proficiency in conducting comparative effectiveness trials for advanced ophthalmic therapeutics, focusing on degenerative eye conditions that significantly impact visual function and quality of life.
- Neovascular age-related macular degeneration (nAMD) therapeutic trials
- Anti-VEGF biosimilar comparative studies
- Visual acuity and retinal imaging outcome assessments
The center's research activities emphasize rigorous evaluation of biosimilar medications for retinal diseases, utilizing standardized measurement protocols such as ETDRS letter scoring and Best Corrected Visual Acuity (BCVA) assessments. With experience in equivalence trials comparing novel therapeutics to established reference products, the facility contributes valuable evidence for expanding treatment options in age-related macular degeneration, one of the leading causes of vision loss in aging populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicinski Centar Po Otcni Bolesti D-R Marinovi OOD
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Trial Comparing Efficacy, Safety, and Immunogenicity of Aflibercept (RBS-001) Versus Aflibercept in Neovascular Age-Related Macular Degeneration | Rophibio Inc. | Phase III | Not Recruiting | — | Apr 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.